Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
PRAX Stock Summary
Top 10 Correlated ETFs
PRAX
In the News
Praxis (PRAX) Surges on Positive Epilepsy Study Results
Praxis (PRAX) reports strong response rates across both study arms in a phase IIa proof of concept study for epilepsy patients with PPR.
Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing
Praxis Precision Medicines, Inc. results from the phase 3 Essential3 program, using ulixacaltamide for the treatment of patients with essential tremor, expected in the 2nd half of 2024. Company believes that the essential tremor U.S. market opportunity could be $4 billion. Positive data achieved in phase 2 study, using PRAX-628 for focal epilepsy; Phase 2b study targeting this very same patient population to be initiated 2nd half of 2024.
What Makes Praxis Precision Medicines, Inc. (PRAX) a Strong Momentum Stock: Buy Now?
Does Praxis Precision Medicines, Inc. (PRAX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think Praxis Precision Medicines, Inc. (PRAX) Could Surge 134.35%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 134.4% in Praxis Precision Medicines, Inc. (PRAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates
Praxis Precision Medicines, Inc. (PRAX) came out with a quarterly loss of $2.97 per share versus the Zacks Consensus Estimate of a loss of $3.15. This compares to loss of $13.04 per share a year ago.
Praxis Precision Medicines, Inc. (PRAX) Just Flashed Golden Cross Signal: Do You Buy?
After reaching an important support level, Praxis Precision Medicines, Inc. (PRAX) could be a good stock pick from a technical perspective. PRAX recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference
BOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside discussion at the Piper Sandler Healthcare Conference on November 28, 2023 at 10:00am. The event will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company's website at www.praxismedicines.com.
Praxis Precision Medicines, Inc. (PRAX) Loses -32.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Praxis Precision Medicines, Inc. (PRAX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
New Strong Buy Stocks for October 11th
PBF, PRAX, CPRX, MFA and GFF have been added to the Zacks Rank #1 (Strong Buy) List on October 11, 2023.
Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be presenting analyses highlighting patient-focused endpoints from its Essential1 study of ulixacaltamide (PRAX-944) in essential tremor (ET) at The International Parkinson and Movement Disorder Society's (MDS) International Congress of Parkinson's Disease and Movement Disorders®, taking place in Copenhagen, Denmark.
PRAX Financial details
PRAX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -2.07 | -1.62 | -3.93 | -4.62 | -0.02 | |
Operating cash flow per share | -1.95 | -1.38 | -2.93 | -4.01 | -0.02 | |
Free cash flow per share | -1.95 | -1.37 | -2.96 | -4.02 | -0.02 | |
Cash per share | 2.61 | 7.75 | 6.5 | 2.18 | 0.01 | |
Book value per share | 2.34 | 7.51 | 5.91 | 1.65 | 0.01 | |
Tangible book value per share | 2.34 | 7.51 | 5.91 | 1.65 | 0.01 | |
Share holders equity per share | 2.34 | 7.51 | 5.91 | 1.65 | 0.01 | |
Interest debt per share | 0.08 | 0.02 | 0.2 | 0.09 | 0 | |
Market cap | 7.16B | 31.58B | 12.55B | 1.65B | 146.92B | |
Enterprise value | 7.12B | 31.29B | 12.41B | 1.59B | 146.84B | |
P/E ratio | -201.7 | -510.89 | -75.18 | -7.72 | -1.19K | |
Price to sales ratio | 0 | 0 | 0 | 0 | 60.04K | |
POCF ratio | -214.33 | -600.18 | -100.72 | -8.89 | -1.32K | |
PFCF ratio | -213.67 | -600.22 | -99.88 | -8.87 | -1.32K | |
P/B Ratio | 178.57 | 109.87 | 50.02 | 21.62 | 2.11K | |
PTB ratio | 178.57 | 109.87 | 50.02 | 21.62 | 2.11K | |
EV to sales | 0 | 0 | 0 | 0 | 60.01K | |
Enterprise value over EBITDA | -200.22 | -504.89 | -74.17 | -7.39 | -1.17K | |
EV to operating cash flow | -213.03 | -594.55 | -99.64 | -8.58 | -1.32K | |
EV to free cash flow | -212.38 | -594.6 | -98.81 | -8.56 | -1.32K | |
Earnings yield | 0 | 0 | -0.01 | -0.13 | 0 | |
Free cash flow yield | 0 | 0 | -0.01 | -0.11 | 0 | |
Debt to equity | 0.04 | 0 | 0.03 | 0.06 | 0.04 | |
Debt to assets | 0.03 | 0 | 0.03 | 0.04 | 0.03 | |
Net debt to EBITDA | 1.22 | 4.77 | 0.8 | 0.27 | 0.63 | |
Current ratio | 6.67 | 19.23 | 7.64 | 3.12 | 5.39 | |
Interest coverage | 0 | 0 | 0 | 513.09 | 0 | |
Income quality | 0.94 | 0.85 | 0.75 | 0.86 | 0.9 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | -0.01 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 17.19 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 35.46 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0.01 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | -0.02 | |
Capex to depreciation | -2.78 | 0.08 | -5.77 | -1.06 | -0.12 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 10.16 | |
Graham number | 10.42 | 16.52 | 22.86 | 13.1 | 0.07 | |
ROIC | -0.83 | -0.21 | -0.63 | -2.54 | -1.69 | |
Return on tangible assets | -0.74 | -0.2 | -0.57 | -1.85 | -1.4 | |
Graham Net | 2.17 | 7.34 | 5.51 | 1.33 | 0.01 | |
Working capital | 38.68M | 286.61M | 249.79M | 75.32M | 69.13M | |
Tangible asset value | 40.11M | 287.46M | 250.81M | 76.11M | 69.67M | |
Net current asset value | 37.92M | 286.61M | 245.47M | 71.82M | 66.6M | |
Invested capital | 0.04 | 0 | 0.03 | 0.06 | 0.04 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 3.03M | 3.38M | 7.43M | 12.73M | 10.24M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 1.43K | 2K | 2.47K | 4.57K | 4.91K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.25 | 0.18 | 0.15 | 0.08 | 0.07 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.89 | -0.22 | -0.67 | -2.8 | -1.77 | |
Capex per share | -0.01 | 0 | -0.02 | -0.01 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0.01 | 0.01 | 0 | 0.06 | |
Net income per share | -0.86 | -0.69 | -0.49 | -0.18 | -2.97 | |
Operating cash flow per share | -0.61 | -0.62 | -0.45 | -0.17 | -2.63 | |
Free cash flow per share | -0.61 | -0.62 | -0.45 | -0.17 | -2.64 | |
Cash per share | 2.11 | 1.62 | 1.78 | 0.75 | 8.97 | |
Book value per share | 1.6 | 1.21 | 1.51 | 0.64 | 7.69 | |
Tangible book value per share | 1.6 | 1.21 | 1.51 | 0.64 | 7.69 | |
Share holders equity per share | 1.6 | 1.21 | 1.51 | 0.64 | 7.69 | |
Interest debt per share | 0.09 | 0.08 | 0.04 | 0.02 | 0.28 | |
Market cap | 1.7B | 644.67M | 1.2B | 3.48B | 201.87M | |
Enterprise value | 1.64B | 567.09M | 1.08B | 3.38B | 123.07M | |
P/E ratio | -10.39 | -4.38 | -8.77 | -35.3 | -1.88 | |
Price to sales ratio | 0 | 943.88 | 1.54K | 7.43K | 391.99 | |
POCF ratio | -58.99 | -19.63 | -38.54 | -149.81 | -8.46 | |
PFCF ratio | -58.99 | -19.63 | -38.54 | -149.81 | -8.44 | |
P/B Ratio | 22.33 | 10 | 11.39 | 40.09 | 2.9 | |
PTB ratio | 22.33 | 10 | 11.39 | 40.09 | 2.9 | |
EV to sales | 0 | 830.29 | 1.39K | 7.22K | 238.97 | |
Enterprise value over EBITDA | -39.61 | -14.89 | -31.04 | -132.45 | -4.44 | |
EV to operating cash flow | -57 | -17.27 | -34.66 | -145.58 | -5.16 | |
EV to free cash flow | -57 | -17.27 | -34.66 | -145.58 | -5.15 | |
Earnings yield | -0.02 | -0.06 | -0.03 | -0.01 | -0.13 | |
Free cash flow yield | -0.02 | -0.05 | -0.03 | -0.01 | -0.12 | |
Debt to equity | 0.06 | 0.07 | 0.03 | 0.03 | 0.04 | |
Debt to assets | 0.04 | 0.04 | 0.02 | 0.03 | 0.03 | |
Net debt to EBITDA | 1.38 | 2.04 | 3.48 | 3.85 | 2.85 | |
Current ratio | 3.12 | 3.08 | 5.31 | 6.15 | 5.39 | |
Interest coverage | 394.79 | 359.35 | 0 | 0 | 0 | |
Income quality | 0.7 | 0.88 | 0.91 | 0.94 | 0.89 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | -0.01 | -0.01 | -0.01 | -0.01 | 0 | |
Sales general and administrative to revenue | 0 | 19.43 | 12.97 | 18.64 | 19.29 | |
Research and developement to revenue | 0 | 37.34 | 32.8 | 36.88 | 35.7 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | -0.1 | |
Capex to depreciation | 0 | 0 | 0 | 0 | -0.45 | |
Stock based compensation to revenue | 0 | 11.12 | 7.39 | 12.31 | 11.12 | |
Graham number | 5.56 | 4.35 | 4.09 | 1.62 | 22.65 | |
ROIC | -0.49 | -0.52 | -0.31 | -0.28 | -0.37 | |
Return on tangible assets | -0.36 | -0.37 | -0.26 | -0.23 | -0.31 | |
Graham Net | 1.29 | 0.98 | 1.38 | 0.6 | 6.96 | |
Working capital | 75.32M | 63.75M | 105.4M | 86.54M | 69.13M | |
Tangible asset value | 76.11M | 64.47M | 105.63M | 86.76M | 69.67M | |
Net current asset value | 71.82M | 60.49M | 101.96M | 83.36M | 66.6M | |
Invested capital | 0.06 | 0.07 | 0.03 | 0.03 | 0.04 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 12.4M | 15.83M | 12.5M | 7.59M | 6.49M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 4.39K | 4.98K | 2.31K | 2.01K | 4.71K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.02 | 0.02 | 0.04 | 0.04 | 0.02 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.54 | -0.57 | -0.32 | -0.28 | -0.39 | |
Capex per share | 0 | 0 | 0 | 0 | -0.01 |
PRAX Frequently Asked Questions
What is Praxis Precision Medicines, Inc. stock symbol ?
Praxis Precision Medicines, Inc. is a US stock , located in Boston of Ma and trading under the symbol PRAX
What is Praxis Precision Medicines, Inc. stock quote today ?
Praxis Precision Medicines, Inc. stock price is $60.945 today.
Is Praxis Precision Medicines, Inc. stock public?
Yes, Praxis Precision Medicines, Inc. is a publicly traded company.